First Berlin Initiates Buy Rating on Lisata Therapeutics

On January 21, 2025, First Berlin Equity Research initiated coverage on Lisata Therapeutics Inc, assigning a "BUY" recommendation with a target price of USD 15.00. Analyst Christian Orquera highlighted Lisata's focus on developing therapies for advanced solid tumors.

Lisata Therapeutics, formerly Caladrius Biosciences, has gained attention for its lead drug candidate, certepetide. This peptide enhances the penetration of co-administered anti-cancer drugs and modifies the tumor microenvironment, potentially increasing the efficacy of therapies. The clinical-stage company is conducting seven trials across various cancer types, including pancreatic and cholangiocarcinoma.

Lisata has also secured a strategic partnership with Qilu Pharmaceuticals for the rights to certepetide in Greater China, potentially worth up to USD 221 million. The year 2025 is pivotal as Lisata anticipates results from ongoing trials, potentially driving its stock value.